Advanced search
Publication Cover
Immunotherapy Volume 16, 2024 - Issue 6
Submit an article Journal homepage
56
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Immune Checkpoint Inhibitors in Follicular Dendritic Cell Sarcoma

Tarek Assi1 International Department, Gustave Roussy, 114, Rue Edouard Vaillant, Villejuif, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5579-5264
ORCID Icon &
Axel Le Cesne1 International Department, Gustave Roussy, 114, Rue Edouard Vaillant, Villejuif, FranceORCID Iconhttps://orcid.org/0000-0002-8006-8659
ORCID Icon
Pages 341-344 | Received 06 Sep 2023, Accepted 29 Jan 2024, Published online: 16 Feb 2024

References

  • Kairouz S , HashashJ, KabbaraW, MchaylehW, TabbaraIA. Dendritic cell neoplasms: an overview. Am. J. Hematol.82(10), 924–928 (2007).
  • Steinman RM , BanchereauJ. Taking dendritic cells into medicine. Nature449(7161), 419–426 (2007).
  • Monda L , WarnkeR, RosaiJ. A primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation. A report of 4 cases. Am. J. Pathol.122(3), 562 (1986).
  • Facchetti F , SimbeniM, LorenziL. Follicular dendritic cell sarcoma. Pathologica113(5), 316 (2021).
  • Chan ACL , ChanKW, ChanJKC, AuWY, HoWK, NgWM. Development of follicular dendritic cell sarcoma in hyaline-vascular Castleman’s disease of the nasopharynx: tracing its evolution by sequential biopsies. Histopathology38(6), 510–518 (2001).
  • Lin O , FrizzeraG. Angiomyoid and follicular dendritic cell proliferative lesions in Castleman’s disease of hyaline-vascular type: a study of 10 cases. Am. J. Surg. Pathol.21(11), 1295–1306 (1997).
  • Shah P , ShahS, AgostinoN. Disease response to pazopanib in follicular dendritic cell sarcoma. Case Rep. Oncol.13(3), 1131–1135 (2020).
  • Saygin C , UzunaslanD, OzgurogluM, SenocakM, TuzunerN. Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series. Crit. Rev. Oncol. Hematol.88(2), 253–271 (2013).
  • Chan JK , FletcherCD, NaylerSJ, CooperK. Follicular dendritic cell sarcoma: clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized. Cancer79(2), 294–313 (1997).
  • Jain P , MilgromSA, PatelKPet al. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br. J. Haematol.178(3), 403–412 (2017).
  • Khalid T , FolmanR. Symptoms in cancer patients and an unusual tumor: Case 3. Follicular dendritic cell sarcoma. J. Clin. Oncol.23(36), 9425–9426 (2005).
  • Conry RM . Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review. Clin. Sarcoma Res.4(1), 6 (2014).
  • Oshiro H , TomeY, KiyunaTet al. Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model. Tissue Cell58, 17–23 (2019).
  • Azim HA , ElsedewyE, AzimHAJr. Imatinib in the treatment of follicular dendritic sarcoma: a case report and review of literature. Onkologie30(7), 381–384 (2007).
  • Borghaei H , Paz-AresL, HornLet al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N. Engl. J. Med.373(17), 1627–1639 (2015).
  • Tawbi HA , BurgessM, BolejackVet al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, Phase II trial. Lancet Oncol.18(11), 1493–1501 (2017).
  • Agaimy A , MichalM, HadravskyL, MichalM. Follicular dendritic cell sarcoma: clinicopathologic study of 15 cases with emphasis on novel expression of MDM2, somatostatin receptor 2A, and PD-L1. Ann. Diagn. Pathol.23, 21–28 (2016).
  • Cingam SR , AlShaarani M, TakalkarA, PeddiP. Follicular dendritic sarcoma masquerading as fibrosing mediastinitis. Case Rep.2017, bcr-2016 (2017).
  • Lee M , Bernabe-RamirezC, RamirezDC, MakiRG. Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab. BMJ Case Rep.13(4), e234363 (2020).
  • Rosenbaum E , QinL-X, DicksonMAet al. Interim results of a Phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS). J. Clin. Oncol.41(Suppl. 16), 11518 (2023).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.